Summer 2025, Volume 10, Issue 38 (20-33) DOI: 10.22034/pmj.2025.728528

Personalized & Precision Medicine Journal

Homepage: www.pmjournal.ir

The Role of the Microbiome in Designing Personalized Therapies: Emerging Approaches in Immune and Metabolic Regulation

Hafza Zubair [1,*]

[1] **COMSATS Univerity, Islamabad, Pakistan.**

ARTICLE INFO

Paper Type: Review Article

Submitted: 2025-04-22
Accepted: 2025-08-18

Keywords:
Microbiome
Personalized Medicine
Metabolic Regulation
Microbial Dysbiosis
Disease Prevention

Corresponding author:
Hafza Zubair
Email:hafsazbzz@gmail.com

ABSTRACT

The human microbiome, consisting of trillions of microorganisms living in and on the body, plays a critical role in maintaining physiological balance and health. Recent advancements in microbiome research have demonstrated its profound influence on immune function, metabolic regulation, and disease pathogenesis. Personalized therapies that integrate the microbiome into treatment strategies have emerged as a promising approach to optimize patient outcomes. This review explores the current understanding of the microbiome's role in immune and metabolic regulation and highlights emerging approaches for incorporating microbiome-based interventions into personalized therapy regimens. We discuss the potential of microbiome modulation to enhance immune responses, improve metabolic health, and provide novel therapeutic options for diseases such as cancer, diabetes, autoimmune disorders, and inflammatory bowel diseases (IBD).

How to Cite this Article:
H, Zubair. "The Role of the Microbiome in Designing Personalized Therapies: Emerging Approaches in Immune and Metabolic Regulation" Personalized & Precision Medicine Journal, Vol. 10, no. 38, pp. 20- 33.

INTRODUCTION

The human microbiome, which comprises bacteria, viruses, fungi, and archaea, is a varied and always shifting community of microorganisms found at many anatomical sites on and within the human body (1). The gut, skin, oral cavity, and other mucosal surfaces have especially high microbial counts. Taken holistically, the cells of the microbiome not only outnumber human cells but also have a genomic content far more complex and varied than the human genome (2). This large reservoir of microbial genes codes for many of the numerous biochemical events necessary for host physiology, including digestion, vitamin synthesis, immune system modulation, and defense against pathogenic invaders (3, 4). Research advances motivated by high-throughput sequencing technologies and systems biology approaches over the past ten years have greatly enhanced the vital contribution of the microbiome in human health and disease (5). Now well established is the importance of the microbiome as a fundamental regulating organ influencing many different physiological processes, particularly those connected to immune surveillance and metabolic control (6).

Because of its essential role in maintaining immunological balance, enhancing nutrient absorption and metabolism, and building a necessary barrier against enteric pathogens, the gut microbiome has attracted the most scientific interest of all the microbial habitats in the human body (7). A good gut flora supports metabolic homeostasis, helps immune system development and education, and interacts intricately and usually favorably with host signaling paths (8). On the other hand, a growing number of

pathological conditions have been linked to changes in the microbiota's composition or function, known as microbial dysbiosis. Inflammatory and autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease), metabolic disorders (e.g., obesity, type 2 diabetes), cardiovascular diseases, neurodevelopmental and neurodegenerative disorders, and even cancers are among them (9). The human microbiome has become a compelling target for therapeutic intervention due to its pivotal role in both health and disease. Personalized medicine, a clinical paradigm that aims to tailor medical treatment to each patient's unique characteristics, is one area in which microbiome-based strategies are being incorporated more and more (10). This method considers an individual's distinct genetic profile, lifestyle choices, environmental exposures, and—more recently—their microbial makeup. Clinicians may be able to create more precise and effective treatments with better results and fewer side effects by utilizing knowledge about a patient's microbiome (11, 12). The function of the microbiome in immune and metabolic regulation will be discussed in this review, along with new approaches to using microbiome-based therapies in individualized treatment.

The Microbiome and Immune Regulation

The human microbiome, particularly the gut flora, plays a significant role in shaping and regulating the immune system throughout life. From the time of birth, microbial colonization of the body—shaped by elements including mode of delivery, nursing, antibiotic exposure, and environmental influences—begins a complex dialogue between host and microbe needed for appropriate immune education and function (13). Early microbial exposures provide the basis of immune tolerance and defense since they help the immune system to precisely differentiate between benign environmental or dietary antigens and dangerous pathogens. The largest immune organ in the human body, gut-associated lymphoid tissue (GALT), is fundamental in this process. Especially placed at the junction of the host and the dense microbial populations of the gastrointestinal tract, GALT hosts an amazing spectrum of immune cells (15). Toll-like receptors (TLRs) and NOD-like receptors (NLRs) on host immune cells identify microbial signals, including microbial-associated molecular patterns (MAMPs), including lipopolysaccharides and peptidoglycans, by means of pattern recognition receptors (PRRs). These interactions start signaling cascades that mold the growth and activity of the adaptive and natural branches of the immune system (16). Above all, the gut flora shapes the differentiation of immune cells, including regulatory T cells (Tregs), Th17 cells, and many dendritic cell subsets (17), so preserving mucosal immune homeostasis and preventing too strong inflammatory responses. Moreover, microbial metabolites such as short-chain fatty acids (SCFAs) like butyrate and propionate—play a significant immunomodulatory role by enhancing epithelial barrier integrity, promoting anti-inflammatory cytokine production, and supporting the expansion of regulatory immune populations (18). Often called dysbiosis, changes in the composition or operation of the microbiome can cause immune dysregulation, raising susceptibility to infections, chronic inflammation, and autoimmune diseases (19). Evidence from animal models as well as human studies has linked altered microbiota profiles to diseases including inflammatory bowel disease (IBD), allergies, rheumatoid arthritis, and multiple sclerosis (20). All things considered, the microbiome is a needed architect and immune system regulator that coordinates a well-tuned equilibrium between immune activation and tolerance. Knowing these interactions not only helps one understand immune-related diseases but also creates new directions for the microbiome.

Immune System Development and Microbial Influence

Particularly in early life, the microbiome is absolutely essential since it determines the maturation and functional calibration of the immune system. Different microbial communities during crucial developmental windows such as birth, infancy, and early childhood—allow suitable differentiation and activation of many immune cell types, including T lymphocytes, dendritic cells, macrophages, and B cells (22). These natural cues help the immune repertoire to distinguish between self and non-self as well as between benign antigens and dangerous pathogens, so guiding it (23).

Studies on germ-free animal models provide strong proof of the fundamental function of the microbiome in immune development. Germ-free mice show severe immune deficits (24), having been raised in sterile conditions and so free of any microbial colonization. Among these are underdeveloped secondary lymphoid organs, including Peyer's patches and mesenteric lymph nodes, low secretory immunoglobulin A (IgA), altered T cell populations, and inadequate responses to infections (25). These findings underline the significant part microbial-derived signals including microbial-associated molecular patterns (MAMPs) and microbial metabolites drive the structural and functional maturation of the immune system (26).

Moreover, apart from supporting immune activation and defense, the microbiome is equally vital in producing immune tolerance (27). This means encouraging the synthesis of anti-inflammatory cytokines, including IL-10 and TGF-β, as well as the spread of regulatory T cells (Tregs), which, taken together, help to control too strong or inappropriate immune responses (28). Strengthening mucosal barrier function and modifying antigen-presenting cell activity helps the microbiota

help stop the immune system from launching assaults against benign environmental agents, dietary proteins, or the body's own tissues (29).

Especially in early life, disruptions to this delicate microbial-immune balance can have long-term consequences and are mostly related to the development of autoimmune and allergic diseases, including type 1 diabetes, asthma, inflammatory bowel disease, and systemic lupus erythematosus (30). Maintaining a varied and balanced microbiome during early immune development is therefore not only fundamental for proving immune competency but also for reducing the lifetime risk of immune-mediated diseases. Especially in early life, the microbiome is absolutely essential for the maturation and functional calibration of the immune system (21). Appropriate differentiation and activation of several immune cell types, including T lymphocytes, dendritic cells, macrophages, and B cells, depend on exposure to different microbial communities during key developmental windows—such as birth, infancy, and early childhood (22). Natural stimuli like these microbial exposures help the immune system to properly distinguish between harmful pathogens and benign antigens as well as between self and non-self, so shaping the immune repertoire (23).

Studies on germ-free animal models provide convincing data on the fundamental contribution of the microbiome to immune development. Germ-free mice show severe immune deficits (24) raised in sterile surroundings and are therefore free of any microbial colonization. Among these are underdeveloped secondary lymphoid organs such as Peyer's patches and mesenteric lymph nodes, low secretory immunoglobulin A (IgA), altered T cell populations, and poor responses to infections (25). These findings underline the significant role that microbial-derived signals—including microbial-associated molecular patterns (MAMPs) and microbial metabolites—play in driving the structural and functional maturation of the immune system (26).

Moreover, outside of supporting immune activation and defense, the microbiome is equally crucial in producing immune tolerance (27). This entails encouraging the spread of regulatory T cells (Tregs) and the synthesis of anti-inflammatory cytokines like IL-10 and TGF-β, which, taken together, help control too strong or inappropriate immune responses (28). The microbiota helps stop the immune system from launching assaults against benign environmental agents, dietary proteins, or the body's own tissues by strengthening mucosal barrier function and adjusting antigen-presenting cell activity (29). Particularly in early life, disturbances to this delicate microbial-immune balance can have long-term effects and are mostly connected to the development of autoimmune and allergic diseases, including type 1 diabetes, asthma, inflammatory bowel disease, and systemic lupus erythematosus (30). Therefore, preserving a varied and balanced microbiome during early immune development is not only basic for establishing immune competency but also for lowering the lifetime risk of immune-mediated diseases. Especially in early life, the maturation and functional calibration of the immune system depend critically on the microbiome (21). Exposure to different microbial communities during important developmental windows—such as birth, infancy, and early childhood—determines appropriate differentiation and activation of many immune cell types, including T lymphocytes, dendritic cells, macrophages, and B cells (22). Natural stimuli such as these microbial exposures guide the immune repertoire by helping the system to correctly differentiate between benign antigens and harmful pathogens as well as between self and non-self (23). Research on germ-free animal models offers strong evidence about the basic role the microbiome plays in immune development. Raised in sterile surroundings and so devoid of any microbial colonization, germ-free mice show extreme immune deficits (24). Among these are low secretory immunoglobulin A (IgA), underdeveloped secondary lymphoid organs (such as Peyer's patches and mesenteric lymph nodes), changed T cell populations, and poor responses to infections (25). These findings draw attention to the crucial part microbial-derived signals—including microbial-associated molecular patterns (MAMPs) and microbial metabolites—drive in structural and functional maturation of the immune system (26). Moreover, outside of immune activation and defense, the microbiome is equally crucial in generating immune tolerance (27). This means promoting the synthesis of anti-inflammatory cytokines like IL-10 and TGF-β as well as the spread of regulatory T cells (Tregs), which, taken together, help to control too strong or inappropriate immune responses (28). Strengthening mucosal barrier function and altering antigen-presenting cell activity, the microbiota helps prevent the immune system from launching assaults against benign environmental agents, dietary proteins, or the body's own tissues (29). Especially in early life, disruptions to this delicate microbial-immune balance can have long-term consequences and are mostly related to the development of autoimmune and allergic diseases, including type 1 diabetes, asthma, inflammatory bowel disease, and systemic lupus erythematosus (30).

Regulation of Inflammatory Responses

Chronic inflammation has been linked to microbial dysbiosis, which can be defined as an imbalance in the microbiome (31). This imbalance is suspected to be the root cause of the pathogenicity of many diseases. The overproduction of pro-inflammatory cytokines

and the activation of immune cells that are brought on by dysbiosis can lead to various disorders, some of which include inflammatory bowel disease (IBD), rheumatoid arthritis, and asthma (32). On the other hand, a perfectly balanced microbiome will increase the production of anti-inflammatory cytokines, which will in turn promote immunological tolerance. This tolerance is essential for maintaining immune homeostasis (33).

Microbiome and Immune Therapy

The microbiome's central role in regulating immune responses drives growing research on its therapeutic use to raise immunotherapy's efficacy and precision (34). An increasing number of data points inside the framework of cancer treatment point to the composition and diversity of the gut microbiota as having a major influence on patient responses to immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 treatments (35). These inhibitors rely on a strong and responsive immune system—one that is, in part, shaped by microbial signals—that reactives T-cells suppressed by tumor-associated mechanisms (36). Studies on particular commensal bacterial species including Akkermansia muciniphila, Bifidobacterium longum, and Faecalibacterium prausnitzii have linked improved clinical outcomes in patients undergoing ICI treatment to these organisms (37) and enhanced anti-tumor immunity. These helpful bacteria seem to help T-cell priming and proliferation, change dendritic cell function, and boost the generation of inflammatory cytokines that support tumor surveillance and destruction (38). From dietary changes and customized probiotic supplements to next-generation microbial consortia, personalized microbiome-targeted treatments from which immunotherapy outcomes in cancer patients could be improved are thus under active research as adjunct strategies (39). Reversing the gut flora to favor immunostimulatory profiles could increase therapeutic efficacy, reduce immune-related adverse events, and so extend the benefits of immunotherapy to a greater population of patients (40). Beyond cancer, the immunomodulating powers of the microbiome have opened fresh paths for the treatment of inflammatory and autoimmune diseases (41). Many autoimmune diseases, including Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), and multiple sclerosis (30), have dysbiosis that is, imbalance in the gut flora. In these disorders, inappropriate immune activation against self-antigens is often linked with altered microbial composition and compromised gut barrier function. Treatments based on the microbiome aim to reach microbial balance and immune tolerance (43). Re-establishing microbial diversity and reducing disease symptoms in some patients has shown promise with methods including fecal microbiota transplantation (FMT), in which stool from a healthy donor is transferred to a patient (44). Likewise, targeted probiotic treatments and modified microbial strains are being developed to especially change immune pathways, reduce inflammation, and increase regulatory T cell responses (45). These findings taken together show the therapeutic possibilities of microbiome modification as a novel approach for cancer prevention and management of autoimmune disease. Validation of the efficacy, safety, and personalization of these interventions will depend mostly on continuous research and clinical trials, so opening the path for microbiome-informed precision medicine (46).

The Microbiome and Metabolic Regulation

Apart from its important contribution to the immune system, the gut microbiome is a major control of host metabolism, so preserving metabolic equilibrium (47). From nutrient absorption to energy harvest to glucose use to lipid metabolism and storage, the trillions of microorganisms living in the gastrointestinal tract impact a wide spectrum of metabolic activities (48). A sophisticated network of microbial enzymes and metabolites closely interacting with host signaling paths mediates these activities (49). By fermenting indigestible dietary fibers into short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate (50), the microbiome mostly helps to regulate metabolism. For colonocytes, these SCFAs are both vital energy sources and signaling molecules; they also have systemic effects (51). SCFAs, for example, affect insulin sensitivity, lower inflammation, control appetite by gut-brain axis signaling, and alter the release of gut-derived hormones, including peptide YY (PYY) and glucagon-like peptide-1 (GLP-1), both of which are absolutely vital for glucose homeostasis and satiety (52). Apart from SCFAs, the microbiome controls bile acid metabolism, which is necessary for the breakdown of fats and the control of cholesterol. Primary bile acids produced by the liver are transformed by gut bacteria into secondary bile acids, which function as signaling molecules binding to nuclear receptors, including G-protein-coupled bile acid receptor 1 (TGR5) (53). Controlling lipid and glucose metabolism, inflammation, and energy expenditure depends on these receptors. Therefore, changes in the microbiome can cause a great metabolic effect by dysregulation of these pathways (54, 55). Furthermore, by influencing the effectiveness of calorie extraction from food, the gut flora can control host energy balance. Research on obesity has revealed that those who have it often have different microbial populations marked by higher diet energy extraction capacity (56). All important traits of metabolic

syndrome (57): these changed microbiomes also correlate with low-grade systemic inflammation, enhanced intestinal permeability, and insulin resistance. Importantly, microbial dysbiosis has been linked to the pathogenesis of several metabolic disorders, including obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases (58). Interventions aimed at modulating the gut microbiome—such as prebiotics, probiotics, synbiotics, dietary changes, and fecal microbiota transplantation—are being actively investigated for their potential to restore metabolic balance and improve clinical outcomes in these conditions (59). Importantly, microbial dysbiosis has been linked to the pathogenesis of several metabolic disorders, including obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases (60). Interventions aimed at modulating the gut microbiome—such as prebiotics, probiotics, synbiotics, dietary changes, and fecal microbiota transplantation—are being actively investigated for their potential to restore metabolic balance and improve clinical outcomes in these conditions (61).

Gut Microbiota and Energy Homeostasis

Increasingly acknowledged as major determinants of host energy balance and weight control are the composition and functional capacity of the gut flora (62). Many studies have shown that individuals with obesity and those of normal weight have different gut microbiomes, implying a direct relationship between microbial ecology and metabolic phenotype (63). One of the most consistent results is a changed bacterial phyla: Firmicutes to Bacteroidetes ratio. While Bacteroidetes are decreased, the relative abundance of Firmicutes is usually higher in obese people, a change thought to improve the capacity of the microbiota to extract energy from otherwise indigestible polysaccharides (64). Microbial fermentation systems that break down complex carbohydrates into absorbable short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate (65), generate this increased energy harvest. Not only do these SCFAs offer a direct source of energy up to 10% of daily caloric intake but they also act as strong signaling molecules that change host metabolism in several respects (66). On intestinal and immune cells, for instance, SCFAs interact with G-protein-coupled receptors (e.g., GPR41 and GPR43) to affect appetite control, fat storage, and insulin output. While propionate is important in gluconeogenesis and lipid metabolism in the liver, butyrate in particular provides the main energy source for colonocytes and shows anti-inflammatory and insulin-sensitizing effects (67). Furthermore, under control by microbial metabolites are important gut hormones linked to hunger and satiety, including ghrelin, peptide YY (PYY), and glucagon-like peptide-1 (GLP-1). By their action on the central nervous system, these hormones control food intake and impact peripheral glucose metabolism and fat storage (68). An imbalance in the gut microbial community, or dysbiosis, can reduce the synthesis of these important metabolites, so aggravating hyperphagia, insulin resistance, and lipid accumulation features of metabolic syndrome and obesity (69). Beyond SCFAs, other microbial products such as lipopolysaccharides (LPS), branched-chain amino acids (BCAAs), and secondary bile acids can also influence energy homeostasis and metabolic inflammation (70). For instance, increased translocation of LPS into the bloodstream—a consequence of increased gut permeability in dysbiosis—has been associated with low-grade chronic inflammation, or "metabolic endotoxemia," which contributes to insulin resistance and adiposity (71). Given this intricate interplay between the gut microbiome and host energy regulation, therapeutic modulation of the microbiota has emerged as a promising strategy to combat obesity and related metabolic disorders (72). Interventions such as prebiotic and probiotic supplementation, dietary fiber enrichment, fecal microbiota transplantation (FMT), and next-generation microbial therapies aim to restore a favorable microbiome composition and enhance SCFA production (73). These strategies hold potential for promoting energy balance, improving glucose metabolism, and supporting weight loss in individuals with metabolic dysfunction (74).

Microbiome and Insulin Resistance

Basic components of metabolic diseases, including type 2 diabetes mellitus (T2DM), obesity, and metabolic syndrome (75), in which case body cells fail to react properly to insulin, are insulin resistance. Rising data in recent years reveals that the gut microbiome is a main actor in the pathogenesis and possible therapy of insulin resistance since it influences glucose metabolism and insulin sensitivity (76). By synthesis of microbial metabolites, especially short-chain fatty acids (SCFAs) such as as acetate, propionate, and butyrate (77), the microbiome clearly affects insulin sensitivity. Made by fermenting dietary fibers, these SCFAs act as signaling molecules engaging specific receptors (e.g., GPR41 and GPR43) on enteroendocrine and immune cells, so activating pathways that improve insulin action (78). SCFAs not only reduce appetite and satiety but also raise pancreatic β-cell activity and insulin sensitivity in peripheral tissues by inducing the release of gut hormones,, including glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Linked increasingly to the pathogenesis of insulin resistance is dysbiosis, defined by an imbalance in the composition and activity of the gut microbial

population (80). One finds negative metabolic and immunological effects of perturbation of the delicate equilibrium between beneficial and perhaps harmful microorganisms (81). Mostly causing both local and systemic inflammation, dysbiosis also significantly influences insulin signaling. Usually resulting from enhanced intestinal permeability, this inflammatory disease lets bacterial components,, including lipopolysaccharides (LPS), translocate into the bloodstream (82). These endotoxins in circulation start natural immune reactions that produce chronic low-grade inflammation in key metabolic tissues, including skeletal muscle, liver, and adipose tissue, so modulating the insulin receptor signaling cascade. This interference reduces the cellular insulin response, so causing metabolic dysfunction and hyperglycemia (83). Moreover, dysbiosis is associated with a reduction in beneficial microbial metabolites such as short-chain fatty acids (SCFAs), which play protective roles in maintaining insulin sensitivity by modulating gut hormone secretion, enhancing anti-inflammatory pathways, and preserving gut barrier integrity (84). The loss of these key roles aggravates metabolic abnormalities, so promoting a vicious cycle that increases insulin resistance and type 2 diabetes (85). Given the central role the microbiome performs in regulating many processes, restoring a healthy and balanced microbial ecosystem presents a possible therapeutic route (86). Dietary interventions that aim to increase the consumption of whole grains, fermented products, and foods high in fiber particularly help beneficial bacteria that are capable of producing SCFAs and other bioactive compounds to grow (87). Prebiotics which provide substrates that support the growth of such microorganisms and probiotics which add live beneficial microorganisms have shown promise in clinical and preclinical studies to improve insulin sensitivity by reducing inflammation and strengthening metabolic signaling pathways (88). Aiming not only to control blood glucose levels but also to solve underlying pathophysiological mechanisms contributing to metabolic diseases, these microbiome-targeted strategies offer a complementary approach to conventional treatments (89). Personalized medicine approaches for the prevention and treatment of insulin resistance and type 2 diabetes (90) will be advanced by ongoing research to maximize these interventions, ascertain appropriate strains and dosages, and customize therapies to individual microbiome profiles.

Microbiome and Obesity

Since its frequency shockingly fast increases everywhere, obesity has become a major global health issue (91). Although a complicated interaction of genetic, environmental, and lifestyle elements clearly causes obesity, growing evidence emphasizes the gut microbiome as the main actor in controlling body weight and distribution of fat (92). Obesity is shaped by several processes, including modulation of energy harvest from the diet, control of host metabolism, and interaction with hormonal and immune pathways (93). The gut microbial community shapes obesity by means of these mechanisms. As was already noted, differences in the relative abundance and diversity of gut bacteria can affect the efficiency with which dietary nutrients are extracted and converted into useable energy (94). Higher ratios of Firmicutes to Bacteroidetes have been linked to enhanced capacity for fermenting complex polysaccharides into absorbable calories, so helping to explain increasing energy harvest and fat accumulation. Many times, obese people show this profile. This profile changes the lipid metabolism and storage of the host, hence influencing the fat distribution patterns and adiposity (96). This profile affects microbial surroundings as well. In addition to producing energy, the gut microbiome significantly regulates bile acid metabolism, thereby directly influencing the breakdown and absorption of fat. Gut bacteria convert primary bile acids into secondary bile acids which function as signaling molecules by means of receptors like Takeda G-protein receptor 5 (TGR5) and farnesoid X receptor (FXR). These receptors specify control of energy consumption, lipid metabolism, and glucose homeostasis. Changing the signaling routes of perturbingile acid helps dysbiosis affect fat metabolism and increase fat storage, so driving obesity (98). These results have spurred much research on recently developed therapeutic strategies meant to target the microbiome to combat obesity. Promising in changing the microbial community of the recipient towards a more balanced and metabolically friendly profile, fecal microbiota transplantation (FMT), or transposing gut bacteria from a healthy donor to a recipient, has shown promise (99, 100). While more clinical research is needed to confirm its long-term safety and efficacy, preliminary studies indicate that FMT might reduce adiposity (101) and enhance metabolic parameters. Apart from FMT, prebiotics and probiotics are easily accessible and could be helpful techniques to change the gut flora. Including inulin and fructooligosaccharides, prebiotics specifically encourage the growth of beneficial bacteria, generating short-chain fatty acids (SCFAs), with anti-obesity effects including appetite control and higher energy expenditure (102). Probiotics which comprise live beneficial microorganisms such as Lactobacillus and Bifidobacterium species have shown varied degrees of success in reducing body weight and improving metabolic health by changing inflammation, gut barrier function, and metabolic signaling pathways. These microbiome-based treatments often rely primarily on diet modification and physical exercise, showing promise as a complement or alternative to traditional

obesity control strategies (104). By addressing the basic microbial causes of obesity and thereby improving weight loss outcomes, these approaches may reduce the risk of complications related to obesity, including type 2 diabetes, cardiovascular diseases, and certain cancers (105).

Personalized Approaches in Microbiome-Based Therapies

Personalized medicine represents a transformative shift in healthcare, moving away from the traditional one-size-fits-all approach toward treatments tailored to an individual's unique genetic, environmental, and lifestyle factors (106). Within this evolving paradigm, the human microbiome has emerged as a vital component due to its profound influence on health and disease. Each person harbors a distinctive microbiome profile shaped by factors such as genetics, diet, geography, age, medication use, and exposure to environmental microbes. This individuality means that microbiome-based therapies must be precisely tailored to the specific microbial landscape of each patient to achieve optimal therapeutic outcomes (107). Advances in high-throughput sequencing technologies and bioinformatics have enabled comprehensive characterization of the microbiome at the species and strain levels, as well as its functional potential (108). These technologies allow clinicians and researchers to identify microbial signatures associated with particular diseases or treatment responses, facilitating the development of precision interventions. For example, in cancer immunotherapy, the presence or absence of certain gut microbial species has been linked to patients' responses to immune checkpoint inhibitors, indicating that microbiome profiling can guide treatment decisions and improve efficacy (109).

Personalized microbiome therapies may include customized probiotic formulations designed to replenish specific beneficial bacteria that are deficient or absent in an individual's gut. Similarly, prebiotic compounds can be selected to promote the growth of target microbes that produce metabolites with therapeutic effects, such as anti-inflammatory SCFAs (110). Additionally, fecal microbiota transplantation (FMT) protocols can be refined by matching donors and recipients based on microbial compatibility to maximize safety and effectiveness (111).

Dietary interventions represent another key avenue for personalization. Since diet profoundly influences the microbiome composition and function, personalized nutrition plans that consider an individual's microbiota can optimize microbial balance and metabolic health (112). Machine learning algorithms and predictive models are increasingly being used to recommend diets that support beneficial microbes, reduce dysbiosis, and improve clinical outcomes (113).

Moreover, personalized microbiome-based therapies have the potential to reduce adverse drug reactions and enhance drug metabolism by accounting for the microbiome's role in modifying pharmacokinetics. This integration of microbiome data into pharmacogenomics promises to further refine personalized treatment regimens (114).

Despite these promising advances, challenges remain in translating personalized microbiome therapies into routine clinical practice. Variability in microbiome sampling, standardization of microbial interventions, regulatory considerations, and the need for large-scale clinical trials must be addressed. Nevertheless, ongoing research and technological innovation are rapidly overcoming these hurdles (115).

Microbiome Profiling for Personalized Medicine

The advent of advanced sequencing technologies has revolutionized our ability to characterize the human microbiome with unprecedented resolution and accuracy. Techniques such as 16S ribosomal RNA (rRNA) gene sequencing and shotgun metagenomic sequencing are at the forefront of this progress, enabling researchers and clinicians to obtain detailed insights into the composition, diversity, and functional potential of microbial communities residing in different body sites (116). 16S rRNA sequencing focuses on sequencing a specific region of the ribosomal RNA gene found in bacteria and archaea. This method allows for the identification and classification of microbes at the genus or sometimes species level, providing a snapshot of the microbial diversity and relative abundance within a sample. Its cost-effectiveness and relatively simple data analysis have made it a widely used tool in microbiome research and clinical studies (117).

Shotgun metagenomics, on the other hand, involves sequencing all genetic material present in a sample, offering a more comprehensive and detailed view. This approach not only identifies microbial species and strains with high resolution but also reveals the functional genes and metabolic pathways present in the microbial community. This functional insight is critical for understanding how microbes influence host physiology, metabolize nutrients, or modulate immune responses (118).

As sequencing costs continue to decrease and computational methods improve, microbiome profiling is becoming more accessible and feasible for routine clinical use (119). Integration with other 'omics' data, such as genomics, metabolomics, and proteomics, is further enhancing our ability to develop comprehensive, personalized health strategies that consider the complex interactions between the microbiome and host (120).

By analyzing an individual's microbiome composition, researchers can identify specific microbial species or strains that may be associated with

health or disease (121). This information can be used to design personalized interventions, such as targeted probiotic treatments, dietary modifications, or the use of prebiotics, to restore microbial balance and optimize health outcomes (122).

By leveraging these technologies, researchers can map an individual's unique microbiome profile, uncovering specific microbial species or strains that are either beneficial or potentially pathogenic (123). For example, an overabundance of certain inflammatory bacterial species might be linked to autoimmune disorders, while the presence of SCFA-producing bacteria may correlate with better metabolic health (124).

This granular understanding enables the design of personalized microbiome interventions. Targeted probiotic treatments can be formulated to introduce or augment specific beneficial strains that are deficient in an individual's microbiome (125). Similarly, prebiotics non-digestible fibers and compounds that selectively feed beneficial microbes can be tailored to support the growth of these key species. Dietary modifications can also be personalized based on microbiome data to promote a balanced microbial ecosystem that supports overall health (126).

Moreover, microbiome profiling can assist in disease risk assessment and early diagnosis, identifying microbial signatures that precede or predict disease onset. This predictive capability allows for timely, targeted interventions to prevent disease progression (127). In oncology, for instance, microbiome profiles have been used to predict responses to immunotherapy, guiding personalized treatment plans that maximize efficacy while minimizing side effects.

Gut Microbiome and Diet for Personalized Therapies

Diet is one of the most influential and modifiable factors shaping the gut microbiome throughout life. The types and amounts of food consumed directly affect the diversity, composition, and function of the microbial communities within the gastrointestinal tract (128). Given this close relationship, dietary interventions have become a cornerstone strategy for modulating the microbiome to promote health and prevent or manage disease (129).

Personalized nutrition dietary plans tailored to an individual's unique microbiome composition and metabolic profile holds significant promise in enhancing the efficacy of dietary recommendations and interventions (130). By understanding the specific microbial species and functional capacities present in a person's gut, nutritionists and clinicians can design targeted diets that foster the growth of beneficial microbes while suppressing potentially harmful ones (131). For example, individuals whose microbiomes show an overrepresentation of pathogenic or pro-inflammatory bacteria may benefit from diets rich in dietary fibers and fermented foods. Dietary fibers serve as substrates for beneficial bacteria, especially those that produce short-chain fatty acids (SCFAs) such as butyrate, acetate, and propionate (132). These SCFAs play vital roles in maintaining gut barrier integrity, regulating immune responses, and supporting metabolic health (18). Fermented foods, including yogurt, kefir, sauerkraut, and kimchi, introduce live beneficial microbes and bioactive compounds that further promote microbial diversity and balance (133).

Conversely, personalized dietary approaches may also involve reducing intake of foods that feed harmful bacteria or exacerbate dysbiosis. For example, limiting refined sugars and processed foods that can promote the growth of inflammatory microbes may be particularly important for individuals with metabolic syndrome or inflammatory bowel disease (134).

Moreover, personalized diet plans can be synergistically combined with microbiome-based therapies such as probiotics and prebiotics to enhance therapeutic outcomes. Probiotics live microorganisms that confer health benefits may colonize more effectively and exert greater beneficial effects when supported by a diet that favors their growth and activity (135). Prebiotics, which are nondigestible food components that selectively stimulate beneficial microbes, can be chosen and dosed based on the individual's microbiome to optimize microbial community shifts (136).

This tailored approach is especially critical because the efficacy of probiotics and prebiotics varies widely depending on the host's baseline microbiome composition and diet (137). For instance, a probiotic strain effective in one individual may fail to colonize or provide benefits in another with a different microbial ecosystem. Therefore, integrating microbiome profiling with personalized nutrition enables more precise and effective modulation of the gut microbiome (138).

In addition to disease prevention and management, personalized dietary modulation of the microbiome has implications for a broad range of conditions, including obesity, diabetes, autoimmune diseases, and even mental health disorders through the gut-brain axis (139). By leveraging individual microbiome data, personalized diets can be designed to restore microbial balance, reduce inflammation, and improve metabolic and immune functions (140).

In conclusion, the interplay between diet and the gut microbiome offers a powerful avenue for personalized therapies. Tailoring dietary recommendations based on individual microbiome profiles not only enhances the success of dietary interventions but also maximizes the benefits of complementary microbiome-targeted therapies, paving the way for more effective, personalized healthcare solutions.

CONCLUSION

The microbiome plays a crucial role in regulating both immune and metabolic functions, influencing the development and progression of numerous diseases. Personalized therapies that integrate microbiome modulation offer a promising approach to improving patient outcomes by restoring microbial balance and enhancing the body's natural defense mechanisms. As research advances, new technologies and therapies will emerge to harness the power of the microbiome in treating a wide range of diseases, from autoimmune disorders to metabolic diseases like obesity and diabetes. Moving forward, the combination of personalized medicine and microbiome-based interventions could transform the landscape of healthcare, offering more precise, effective, and individualized treatment strategies for patients.

Author's Contribution

Hafza Zubair was involved in the conceptualization, design and writing of the manuscript draft. The author read and confirmed the final manuscript.

Funding

This study is the outcome of self-directed research carried out without any financial assistance.

Ethics approval and consent to participate

Not applicable.

Conflict of Interest

The author declared no conflict of interest.

Consent for publication

Not Applicable.

REFERENCES

1.Leonard JM, Toro DD. Defining the Microbiome Components (Bacteria, Viruses, Fungi) and Microbiome Geodiversity. Surgical infections. 2023;24(3):208-12.
2.Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. Cancer research. 2017;77(8):1783-812.
3.Eloe-Fadrosh EA, Rasko DA. The human microbiome: from symbiosis to pathogenesis. Annual review of medicine. 2013;64:145-63.
4.Wang B, Wang L, Wang H, Dai H, Lu X, Lee Y-k, et al. Targeting the Gut Microbiota for Remediating Obesity and Related Metabolic Disorders. The Journal of Nutrition. 2021;151(7):1703-16.
5.Aggarwal N, Kitano S, Puah GRY, Kittelmann S, Hwang IY, Chang MW. Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies. Chemical reviews. 2023;123(1):31-72.
6.Hou K, Wu Z-X, Chen X-Y, Wang J-Q, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduction and Targeted Therapy. 2022;7(1):135.
7.Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7(1):135.
8.Zhao Ma, Chu J, Feng S, Guo C, Xue B, He K, et al. Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review. Biomedicine & Pharmacotherapy. 2023;164:114985.
9.Shen Y, Fan N, Ma SX, Cheng X, Yang X, Wang G. Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy. MedComm. 2025;6(5):e70168.
10.Metwaly A, Kriaa A, Hassani Z, Carraturo F, Druart C, Trebicka J, et al. A Consensus Statement on establishing causality, therapeutic applications and the use of preclinical models in microbiome research. Nature Reviews Gastroenterology & Hepatology. 2025;22(5):343-56.
11.Schupack DA, Mars RAT, Voelker DH, Abeykoon JP, Kashyap PC. The promise of the gut microbiome as part of individualized treatment strategies. Nature reviews Gastroenterology & hepatology. 2022;19(1):7-25.
12.Shukla V, Singh S, Verma S, Verma S, Rizvi AA, Abbas M. Targeting the microbiome to improve human health with the approach of personalized medicine: Latest aspects and current updates. Clinical Nutrition ESPEN. 2024;63:813-20.
13.Rodríguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microbial ecology in health and disease. 2015;26:26050.
14.Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Research. 2020;30(6):492-506.
15.Bemark M, Pitcher MJ, Dionisi C, Spencer J. Gut-associated lymphoid tissue: a microbiota-driven hub of B cell immunity. Trends in immunology. 2024;45(3):211-23.
16.Dieterich W, Schink M, Zopf Y. Microbiota in the Gastrointestinal Tract. Medical sciences (Basel, Switzerland). 2018;6(4).
17.Pandiyan P, Bhaskaran N, Zou M, Schneider E, Jayaraman S, Huehn J. Microbiome Dependent Regulation of Tregs and Th17 Cells in Mucosa. 2019;Volume 10 - 2019.
18.Shin Y, Han S, Kwon J, Ju S, Choi TG, Kang I, et al. Roles of Short-Chain Fatty Acids in Inflammatory Bowel Disease. Nutrients. 2023;15(20).
19.Mostafavi Abdolmaleky H, Zhou J-R. Gut Microbiota Dysbiosis, Oxidative Stress,

Inflammation, and Epigenetic Alterations in Metabolic Diseases. Antioxidants [Internet]. 2024; 13(8).
20.Toor D, Wsson MK, Kumar P, Karthikeyan G, Kaushik NK, Goel C, et al. Dysbiosis Disrupts Gut Immune Homeostasis and Promotes Gastric Diseases. Int J Mol Sci. 2019;20(10).
21.Dogra SK, Kwong Chung C, Wang D, Sakwinska O, Colombo Mottaz S, Sprenger N. Nurturing the Early Life Gut Microbiome and Immune Maturation for Long Term Health. Microorganisms. 2021;9(10).
22.Gaufin T, Tobin NH, Aldrovandi GM. The importance of the microbiome in pediatrics and pediatric infectious diseases. Current opinion in pediatrics. 2018;30(1):117-24.
23.Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121-41.
24.Luczynski P, McVey Neufeld KA, Oriach CS, Clarke G, Dinan TG, Cryan JF. Growing up in a Bubble: Using Germ-Free Animals to Assess the Influence of the Gut Microbiota on Brain and Behavior. The international journal of neuropsychopharmacology. 2016;19(8).
25.Bos A, van Egmond M, Mebius R. The role of retinoic acid in the production of immunoglobulin A. Mucosal Immunology. 2022;15(4):562-72.
26.Kogut MH, Lee A, Santin E. Microbiome and pathogen interaction with the immune system. Poultry Science. 2020;99(4):1906-13.
27.Li Z, Xiong W, Liang Z, Wang J, Zeng Z, Kołat D, et al. Critical role of the gut microbiota in immune responses and cancer immunotherapy. Journal of hematology & oncology. 2024;17(1):33.
28.Nazir A, Hussain FHN, Nadeem Hussain TH, Al Dweik R, Raza A. Therapeutic targeting of the host-microbiota-immune axis: implications for precision health. 2025;Volume 16 - 2025.
29.Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492-506.
30.Thomson CA, Morgan SC, Ohland C, McCoy KD. From germ-free to wild: modulating microbiome complexity to understand mucosal immunology. Mucosal Immunology. 2022;15(6):1085-94.
31.Zhang H, Yang Lee BJ, Wang T, Xiang X, Tan Y, Han Y, et al. Microbiota, chronic inflammation, and health: The promise of inflammatome and inflammatomics for precision medicine and healthcare. hLife. 2025.
32.Mousa WK, Chehadeh F, Husband S. Microbial dysbiosis in the gut drives systemic autoimmune diseases. Frontiers in immunology. 2022;13:906258.
33.Shim JA, Ryu JH, Jo Y, Hong C. The role of gut microbiota in T cell immunity and immune mediated disorders. International journal of biological sciences. 2023;19(4):1178-91.
34.Kang X, Lau HC, Yu J. Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy. Cell reports Medicine. 2024;5(4):101478.
35.Zhang M, Liu J, Xia Q. Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target. Experimental hematology & oncology. 2023;12(1):84.
36.Kim SK, Cho SW. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Frontiers in pharmacology. 2022;13:868695.
37.Yousefi Y, Baines KJ, Maleki Vareki S. Microbiome bacterial influencers of host immunity and response to immunotherapy. Cell reports Medicine. 2024;5(4):101487.
38.Marciscano AE, Anandasabapathy N. The role of dendritic cells in cancer and anti-tumor immunity. Seminars in immunology. 2021;52:101481.
39.Jiang S, Ma W, Ma C, Zhang Z, Zhang W, Zhang J. An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome. Gut microbes. 2024;16(1):2341717.
40.Xie J, Liu M, Deng X, Tang Y, Zheng S, Ou X, et al. Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies. iMeta. 2024;3(1):e156.
41.Kamel M, Aleya S, Alsubih M, Aleya L. Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases. Journal of personalized medicine. 2024;14(2).
42.Chang SH, Choi Y. Gut dysbiosis in autoimmune diseases: Association with mortality. Frontiers in cellular and infection microbiology. 2023;13:1157918.
43.Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Internal and emergency medicine. 2024;19(2):275-93.
44.Tian H, Wang X, Fang Z, Li L, Wu C, Bi D, et al. Fecal microbiota transplantation in clinical practice: Present controversies and future prospects. hLife. 2024;2(6):269-83.
45.Sahle Z, Engidaye G, Shenkute Gebreyes D, Adenew B, Abebe TA. Fecal microbiota transplantation and next-generation therapies: A review on targeting dysbiosis in metabolic disorders and beyond. SAGE open medicine. 2024;12:20503121241257486.
46.Mafe AN, Büsselberg D. Modulation of the Neuro–Cancer Connection by Metabolites of Gut Microbiota. Biomolecules [Internet]. 2025; 15(2).
47.Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut microbes.

2012;3(1):4-14.
48.Zhang Y, Chen R, Zhang D, Qi S, Liu Y. Metabolite interactions between host and microbiota during health and disease: Which feeds the other? Biomedicine & Pharmacotherapy. 2023;160:114295.
49.Wu J, Wang K, Wang X, Pang Y, Jiang C. The role of the gut microbiome and its metabolites in metabolic diseases. Protein & cell. 2021;12(5):360-73.
50.Liu J, Tan Y, Cheng H, Zhang D, Feng W, Peng C. Functions of Gut Microbiota Metabolites, Current Status and Future Perspectives. Aging and disease. 2022;13(4):1106-26.
51.He J, Zhang P, Shen L, Niu L, Tan Y, Chen L, et al. Short-Chain Fatty Acids and Their Association with Signalling Pathways in Inflammation, Glucose and Lipid Metabolism. Int J Mol Sci. 2020;21(17).
52.Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Frontiers in endocrinology. 2020;11:25.
53.Masse KE, Lu VB. Short-chain fatty acids, secondary bile acids and indoles: gut microbial metabolites with effects on enteroendocrine cell function and their potential as therapies for metabolic disease. Frontiers in endocrinology. 2023;14:1169624.
54.Devaraj S, Hemarajata P, Versalovic J. The human gut microbiome and body metabolism: implications for obesity and diabetes. Clinical chemistry. 2013;59(4):617-28.
55.de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. Gut. 2022;71(5):1020-32.
56.Sanmiguel C, Gupta A, Mayer EA. Gut Microbiome and Obesity: A Plausible Explanation for Obesity. Current obesity reports. 2015;4(2):250-61.
57.Peña-Durán E, García-Galindo JJ, López-Murillo LD, Huerta-Huerta A, Balleza-Alejandri LR, Beltrán-Ramírez A, et al. Microbiota and Inflammatory Markers: A Review of Their Interplay, Clinical Implications, and Metabolic Disorders. International Journal of Molecular Sciences [Internet]. 2025; 26(4).
58.Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clinical and molecular hepatology. 2021;27(1):22-43.
59.Abenavoli L, Scarlata GGM, Scarpellini E, Boccuto L, Spagnuolo R, Tilocca B, et al. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome. Medicina (Kaunas, Lithuania). 2023;59(3).
60.Yuan H, Wu X, Wang X, Zhou J-Y, Park S. Microbial Dysbiosis Linked to Metabolic Dysfunction-Associated Fatty Liver Disease in Asians: Prevotella copri Promotes Lipopolysaccharide Biosynthesis and Network Instability in the Prevotella Enterotype. International Journal of Molecular Sciences [Internet]. 2024; 25(4).
61.Bandopadhyay P, Ganguly D. Chapter Six - Gut dysbiosis and metabolic diseases. In: Das B, Singh V, editors. Progress in Molecular Biology and Translational Science. 191: Academic Press; 2022. p. 153-74.
62.Ma ZF, Lee YY. The Role of the Gut Microbiota in Health, Diet, and Disease with a Focus on Obesity. Foods [Internet]. 2025; 14(3).
63.Geng J, Ni Q, Sun W, Li L, Feng X. The links between gut microbiota and obesity and obesity related diseases. Biomedicine & Pharmacotherapy. 2022;147:112678.
64.Zsálig D, Berta A, Tóth V, Szabó Z, Simon K, Figler M, et al. A Review of the Relationship between Gut Microbiome and Obesity. Applied Sciences [Internet]. 2023; 13(1).
65.Pant K, Venugopal SK, Lorenzo Pisarello MJ, Gradilone SA. The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases. The American Journal of Pathology. 2023;193(10):1455-67.
66.Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. 2020;Volume 11 - 2020.
67.Du Y, He C, An Y, Huang Y, Zhang H, Fu W, et al. The Role of Short Chain Fatty Acids in Inflammation and Body Health. International Journal of Molecular Sciences [Internet]. 2024; 25(13).
68.Chao J, Coleman RA, Keating DJ, Martin AM. Gut Microbiome Regulation of Gut Hormone Secretion. Endocrinology. 2025;166(4).
69.Cavallari JF, Schertzer JD. Intestinal Microbiota Contributes to Energy Balance, Metabolic Inflammation, and Insulin Resistance in Obesity. Journal of obesity & metabolic syndrome. 2017;26(3):161-71.
70.Yang W, Cong Y. Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases. Cellular & molecular immunology. 2021;18(4):866-77.
71.Byndloss M, Devkota S, Duca F, Niess JH, Nieuwdorp M, Orho-Melander M, et al. The gut microbiota and diabetes: research, translation, and clinical applications - 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetologia. 2024;67(9):1760-82.
72.Zhang K, Zhang Q, Qiu H, Ma Y, Hou N, Zhang J, et al. The complex link between the gut microbiome and obesity-associated metabolic disorders: Mechanisms and therapeutic opportunities. Heliyon. 2024;10(17):e37609.

73.Shan L, Tyagi A, Shabbir U, Chen X, Vijayalakshmi S, Yan P, et al. The Role of Gut Microbiota Modulation Strategies in Obesity: The Applications and Mechanisms. Fermentation [Internet]. 2022; 8(8).
74.O'Riordan KJ, Collins MK, Moloney GM, Knox EG, Aburto MR, Fülling C, et al. Short chain fatty acids: Microbial metabolites for gut-brain axis signalling. Molecular and Cellular Endocrinology. 2022;546:111572.
75.Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. 2023;Volume 14 - 2023.
76.Szymczak-Pajor I, Drzewoski J, Kozłowska M, Krekora J, Śliwińska A. The Gut Microbiota-Related Antihyperglycemic Effect of Metformin. Pharmaceuticals [Internet]. 2025; 18(1).
77.Salamone D, Rivellese AA, Vetrani C. The relationship between gut microbiota, short-chain fatty acids and type 2 diabetes mellitus: the possible role of dietary fibre. Acta diabetologica. 2021;58(9):1131-8.
78.Sivaprakasam S, Prasad PD, Singh N. Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis. Pharmacology & therapeutics. 2016;164:144-51.
79.Liu J, Li F, Yang L, Luo S, Deng Y. Gut microbiota and its metabolites regulate insulin resistance: traditional Chinese medicine insights for T2DM. Frontiers in microbiology. 2025;16:1554189.
80.Shen Y, Fan N, Ma S-x, Cheng X, Yang X, Wang G. Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy. 2025;6(5):e70168.
81.Singh R, Zogg H, Wei L, Bartlett A, Ghoshal UC, Rajender S, et al. Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders. Journal of neurogastroenterology and motility. 2021;27(1):19-34.
82.Patra D, Banerjee D, Ramprasad P, Roy S, Pal D, Dasgupta S. Recent insights of obesity-induced gut and adipose tissue dysbiosis in type 2 diabetes. Frontiers in molecular biosciences. 2023;10:1224982.
83.da Silva Rosa SC, Nayak N, Caymo AM, Gordon JW. Mechanisms of muscle insulin resistance and the cross-talk with liver and adipose tissue. Physiological reports. 2020;8(19):e14607.
84.Nogal A, Valdes AM, Menni C. The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. Gut microbes. 2021;13(1):1-24.
85.Lopez-Pedrosa JM, Camprubi-Robles M, Guzman-Rolo G, Lopez-Gonzalez A, Garcia-Almeida JM, Sanz-Paris A, et al. The Vicious Cycle of Type 2 Diabetes Mellitus and Skeletal Muscle Atrophy: Clinical, Biochemical, and Nutritional Bases. Nutrients. 2024;16(1).
86.Beltrán-Velasco AI, Clemente-Suárez VJ. Harnessing Gut Microbiota for Biomimetic Innovations in Health and Biotechnology. Biomimetics (Basel, Switzerland). 2025;10(2).
87.Singh RK, Chang HW, Yan D, Lee KM, Ucmak D, Wong K, et al. Influence of diet on the gut microbiome and implications for human health. Journal of translational medicine. 2017;15(1):73.
88.Ji J, Jin W, Liu SJ, Jiao Z, Li X. Probiotics, prebiotics, and postbiotics in health and disease. MedComm. 2023;4(6):e420.
89.Gao Y, Li W, Huang X, Lyu Y, Yue C. Advances in Gut Microbiota-Targeted Therapeutics for Metabolic Syndrome. Microorganisms. 2024;12(5).
90.Hrncir T. Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options. Microorganisms. 2022;10(3).
91.Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism: clinical and experimental. 2022;133:155217.
92.Saad MJA, Santos A. The Microbiota and Evolution of Obesity. Endocrine Reviews. 2024;46(2):300-16.
93.Davis CD. The Gut Microbiome and Its Role in Obesity. Nutrition today. 2016;51(4):167-74.
94.Kalnina I, Gudra D, Silamikelis I, Viksne K, Roga A, Skinderskis E, et al. Variations in the Relative Abundance of Gut Bacteria Correlate with Lipid Profiles in Healthy Adults. Microorganisms. 2023;11(11).
95.Gomes AC, Hoffmann C, Mota JF. The human gut microbiota: Metabolism and perspective in obesity. Gut microbes. 2018;9(4):308-25.
96.Moran-Ramos S, López-Contreras BE, Canizales-Quinteros S. Gut Microbiota in Obesity and Metabolic Abnormalities: A Matter of Composition or Functionality? Archives of Medical Research. 2017;48(8):735-53.
97.Staley C, Weingarden AR, Khoruts A, Sadowsky MJ. Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Applied microbiology and biotechnology. 2017;101(1):47-64.
98.Enache R-M, Profir M, Roşu OA, Creţoiu SM, Gaspar BS. The Role of Gut Microbiota in the Onset and Progression of Obesity and Associated Comorbidities. International Journal of Molecular Sciences [Internet]. 2024; 25(22).
99.Hemachandra S, Rathnayake SN, Jayamaha AA, Francis BS, Welmillage D, Kaur DN, et al. Fecal Microbiota Transplantation as an Alternative Method in the Treatment of Obesity. Cureus.

2025;17(1):e76858.
100.Mederle AL, Dima M, Stoicescu ER, Căpăstraru BF, Levai CM, Hațegan OA, et al. Impact of Gut Microbiome Interventions on Glucose and Lipid Metabolism in Metabolic Diseases: A Systematic Review and Meta-Analysis. Life [Internet]. 2024; 14(11).
101.Zhang Z, Mocanu V, Cai C, Dang J, Slater L, Deehan EC, et al. Impact of Fecal Microbiota Transplantation on Obesity and Metabolic Syndrome-A Systematic Review. Nutrients. 2019;11(10).
102.Horvath A, Zukauskaite K, Hazia O, Balazs I, Stadlbauer V. Human gut microbiome: Therapeutic opportunities for metabolic syndrome—Hype or hope? 2024;7(1):e436.
103.Chandrasekaran P, Weiskirchen S, Weiskirchen R. Effects of Probiotics on Gut Microbiota: An Overview. Int J Mol Sci. 2024;25(11).
104.Peckmezian T, Garcia-Larsen V, Wilkins K, Mosli RH, BinDhim NF, John GK, et al. Microbiome-Targeted Therapies as an Adjunct to Traditional Weight Loss Interventions: A Systematic Review and Meta-Analysis. Diabetes, metabolic syndrome and obesity : targets and therapy. 2022;15:3777-98.
105.Napolitano M, Covasa M. Microbiota Transplant in the Treatment of Obesity and Diabetes: Current and Future Perspectives. Frontiers in microbiology. 2020;11:590370.
106.Mathur S, Sutton J. Personalized medicine could transform healthcare. Biomedical reports. 2017;7(1):3-5.
107.Yaqub MO, Jain A, Joseph CE, Edison LK. Microbiome-Driven Therapeutics: From Gut Health to Precision Medicine. Gastrointestinal Disorders [Internet]. 2025; 7(1).
108.Noecker C, McNally CP, Eng A, Borenstein E. High-resolution characterization of the human microbiome. Translational research : the journal of laboratory and clinical medicine. 2017;179:7-23.
109.Hemmati MA, Monemi M, Asli S, Mohammadi S, Foroozanmehr B, Haghmorad D, et al. Using New Technologies to Analyze Gut Microbiota and Predict Cancer Risk. Cells. 2024;13(23).
110.Gulliver EL, Young RB, Chonwerawong M, D'Adamo GL, Thomason T, Widdop JT, et al. Review article: the future of microbiome-based therapeutics. Alimentary pharmacology & therapeutics. 2022;56(2):192-208.
111.Liu Y, Li X, Chen Y, Yao Q, Zhou J, Wang X, et al. Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay. Frontiers in microbiology. 2025;16:1556827.
112.Abeltino A, Hatem D, Serantoni C, Riente A, De Giulio MM, De Spirito M, et al. Unraveling the Gut Microbiota: Implications for Precision Nutrition and Personalized Medicine. Nutrients [Internet]. 2024; 16(22).
113.Rouskas K, Guela M, Pantoura M, Pagkalos I, Hassapidou M, Lalama E, et al. The Influence of an AI-Driven Personalized Nutrition Program on the Human Gut Microbiome and Its Health Implications. Nutrients [Internet]. 2025; 17(7).
114.Mafe AN, Büsselberg D. Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug. Biomedicines [Internet]. 2025; 13(2).
115.Rodriguez J, Cordaillat-Simmons M, Pot B, Druart C. The regulatory framework for microbiome-based therapies: insights into European regulatory developments. npj Biofilms and Microbiomes. 2025;11(1):53.
116.Han D, Gao P, Li R, Tan P, Xie J, Zhang R, et al. Multicenter assessment of microbial community profiling using 16S rRNA gene sequencing and shotgun metagenomic sequencing. Journal of Advanced Research. 2020;26:111-21.
117.Pérez-Bustamante IS, Cruz-Flores R, López-Carvallo JA, Sánchez-Serrano S. Effect of the 16S rRNA Gene Hypervariable Region on the Microbiome Taxonomic Profile and Diversity in the Endangered Fish Totoaba macdonaldi. Microorganisms [Internet]. 2024; 12(11).
118.Bekele GK, Abda EM, Tuji FA, Meka AF, Gemeda MT. Shotgun Metagenomics Reveals Metabolic Potential and Functional Diversity of Microbial Communities of Chitu and Shala Soda Lakes in Ethiopia. Microbiology Research [Internet]. 2025; 16(3).
119.Lee D, Maaskant A, Ngo H, Montijn RC, Bakker J, Langermans JAM, et al. A rapid, affordable, and reliable method for profiling microbiome biomarkers from fecal images. iScience. 2024;27(12).
120.Babu M, Snyder M. Multi-Omics Profiling for Health. Molecular & cellular proteomics : MCP. 2023;22(6):100561.
121.Bars-Cortina D, Ramon E, Rius-Sansalvador B, Guinó E, Garcia-Serrano A, Mach N, et al. Comparison between 16S rRNA and shotgun sequencing in colorectal cancer, advanced colorectal lesions, and healthy human gut microbiota. BMC Genomics. 2024;25(1):730.
122.Oudat Q, Okour A. The Role of Probiotics in Modulating Gut Microbiota and Metabolic Health for Weight Management: A Mini Review. Acta Microbiologica Hellenica [Internet]. 2025; 70(1).
123.D'Urso F, Broccolo F. Applications of Artificial Intelligence in Microbiome Analysis and Probiotic Interventions—An Overview and Perspective Based on the Current State of the Art. Applied Sciences [Internet]. 2024; 14(19).
124.Kim CH. Complex regulatory effects of gut microbial short-chain fatty acids on immune

tolerance and autoimmunity. Cellular & molecular immunology. 2023;20(4):341-50.
125.Mincic AM, Antal M, Filip L, Miere D. Modulation of gut microbiome in the treatment of neurodegenerative diseases: A systematic review. Clinical Nutrition. 2024;43(7):1832-49.
126.Wang S, Xiao Y, Tian F, Zhao J, Zhang H, Zhai Q, et al. Rational use of prebiotics for gut microbiota alterations: Specific bacterial phylotypes and related mechanisms. Journal of Functional Foods. 2020;66:103838.
127.Rozera T, Pasolli E, Segata N, Ianiro G. Machine Learning and Artificial Intelligence in the Multi-Omics Approach to Gut Microbiota. Gastroenterology. 2025.
128.Zhang P. Influence of Foods and Nutrition on the Gut Microbiome and Implications for Intestinal Health. Int J Mol Sci. 2022;23(17).
129.Aziz T, Hussain N, Hameed Z, Lin L. Elucidating the role of diet in maintaining gut health to reduce the risk of obesity, cardiovascular and other age-related inflammatory diseases: recent challenges and future recommendations. Gut microbes. 2024;16(1):2297864.
130.Bianchetti G, De Maio F, Abeltino A, Serantoni C, Riente A, Santarelli G, et al. Unraveling the Gut Microbiome-Diet Connection: Exploring the Impact of Digital Precision and Personalized Nutrition on Microbiota Composition and Host Physiology. Nutrients. 2023;15(18).
131.Rinninella E, Tohumcu E, Raoul P, Fiorani M, Cintoni M, Mele MC, et al. The role of diet in shaping human gut microbiota. Best Practice & Research Clinical Gastroenterology. 2023;62-63:101828.
132.Hills RD, Jr., Pontefract BA, Mishcon HR, Black CA, Sutton SC, Theberge CR. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients. 2019;11(7).
133.Hernández-Calderón P, Wiedemann L, Benítez-Páez A. The microbiota composition drives personalized nutrition: Gut microbes as predictive biomarkers for the success of weight loss diets. Frontiers in nutrition. 2022;9:1006747.
134.Rondinella D, Raoul PC, Valeriani E, Venturini I, Cintoni M, Severino A, et al. The Detrimental Impact of Ultra-Processed Foods on the Human Gut Microbiome and Gut Barrier. Nutrients [Internet]. 2025; 17(5).
135.Markowiak P, Śliżewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients. 2017;9(9).
136.Yasmin A, Butt MS, Afzaal M, van Baak M, Nadeem MT, Shahid MZ. Prebiotics, gut microbiota and metabolic risks: Unveiling the relationship. Journal of Functional Foods. 2015;17:189-201.
137.Mafe AN, Edo GI, Majeed OS, Gaaz TS, Akpoghelie PO, Isoje EF, et al. A review on probiotics and dietary bioactives: Insights on metabolic well-being, gut microbiota, and inflammatory responses. Food Chemistry Advances. 2025;6:100919.
138.Jiang S, Huang S, Zhang Z, Ma W, Han Z, Song Y, et al. Gut microbiota drives structural variation of exogenous probiotics to enhance colonization. Gut microbes. 2025;17(1):2503371.
139.O'Riordan KJ, Moloney GM, Keane L, Clarke G, Cryan JF. The gut microbiota-immune-brain axis: Therapeutic implications. Cell Reports Medicine. 2025;6(3):101982.
140.O'Riordan KJ, Moloney GM, Keane L, Clarke G, Cryan JF. The gut microbiota-immune-brain axis: Therapeutic implications. Cell reports Medicine. 2025;6(3):101982.